7441
Specialized clinical information about coronavirus COVID-19
The situation is rapidly evolving, and information is being constantly updated. Last updated
View FAQs about COVID-19 and people living with HIV
View FAQsUpdated! General Information about COVID-19
UNAIDS
Coronavirus Innovation Map
Global map of innovative solutions created in response to Covid-19.
Johns Hopkins University
Coronavirus (COVID-19) world map
European Commission
Coronavirus response
ECDC
Situation update for the EU/EEA and the UK
USA
Other
International survey on coronavirus
Updated! HIV and COVID-19
COVID-19 (medical information)
WHO
Drug Interaction COVID-19
Drug interactions with experimental COVID-19 therapies.
Updated! Guidelines for treatment of COVID-19
Сontinually updated
SARS-CoV-2 /COVID-19 - Antiviral and immunomodulatory treatment considerations
Guideline of the Swiss Society for Infectious Diseases (SSI) in collaboration with the Swiss Society of Intensive Care Medicine (SSMI)
Updated!
Interim clinical guidance for patients suspected of/confirmed with COVID-19 in Belgium
Inpatient guidance for treatment of COVID-19 in adults and children (University of Michigan,
USA)
Руководство по лечению и поддерживающей терапии пациентов с коронавирусной инфекцией COVID-19
(Италия, Ломбардия)
Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)
(Released by National Health Commission & State Administration of Traditional Chinese Medicine)
Updated! Clinical trials and scientific articles of COVID-19
COVID-19 - Resource Centres of scientific journals
Updated! General
Updated!
Solidarity Therapeutics Trial produces conclusive evidence on the effectiveness of repurposed drugs for COVID-19 in record time
PDF
Updated!
Lopinavir-ritonavir is not an effective treatment for patients hospitalised with COVID-19 (Recovery)
A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence
The pneumonia caused by novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 is a
highly
contagious disease. The World Health Organization (WHO) has declared the ongoing outbreak as
a
global public health emergency. Currently, the research on novel coronavirus is still in the
primary
stage. Based on the current published evidence, we systematically summarizes the
epidemiology,
clinical characteristics, diagnosis, treatment and prevention of knowledge surrounding
COVID-19.
This review in the hope of helping the public effectively recognize and deal with the 2019
novel
coronavirus (SARS-CoV-2), and providing a reference for future studies.
Surface Stability
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
The virus that causes coronavirus disease 2019 (COVID-19) is stable for several hours to
days in
aerosols and on surfaces. The scientists found that severe acute respiratory syndrome
coronavirus 2
(SARS-CoV-2) was detectable in aerosols for up to three hours, up to four hours on copper,
up to 24
hours on cardboard and up to two to three days on plastic and stainless steel.
Updated! Remdesivir
Updated! Vaccine
Updated!
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
Updated!
ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Novel COVID-19 Vaccine Candidate hAd5
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
BCG vaccination to Reduce the impact of COVID-19 in Australian healthcare workers following
Coronavirus Exposure (BRACE) Trial
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2
Infection (in
USA)
Updated! Lopinavir/Ritonavi
New! Corticosteroid dexamethasone
Other agents
A randomized, open label, parallel controlled trial of evaluating the efficacy of
recombinant cytokine
gene-derived protein injection for clearing novel coronavirus in patients with novel
coronavirus
pneumonia (COVID-19)
A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and
safety of
recombinant cytokine gene-derived protein injection in combination with standard therapy in
patients
with novel coronavirus infection
Statements of NGOs
The Position of Correlation-European Harm Reduction Network and EHRA on the
Continuity
of Harm Reduction Services During the COVID-19 Crisis
View FAQs about COVID-19 and people living with HIV
View FAQsIf you have questions or comments about HIV and COVID-19, let us know [email protected]